Clinical Trial

Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will continue to receive Ruxolitinib.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2017-11-01; most recent amendment 2025-03-25.
Status change: Recruiting → Active, Not Recruiting 2021-08-20
Trial Details
NCT Number NCT03333187
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Collaborators: Novartis, Clinical Trial Center North (CTC North GmbH & Co. KG)
Conditions Bone Marrow Fibrosis
Enrollment 87 participants
Start Date 2016-12-21
Primary Completion 2024-10-07 (estimated)
Study Completion 2025-10-07 (estimated)
Updated on ClinicalTrials.gov 2025-03-30